Unresectable Colorectal Liver Metastases Clinical Trial
Official title:
Yttrium-90 Carbon Microspheres in Patients With Unresectable Colorectal Liver Metastases: A Multicentre, Prospective, Open-label, Single-arm Trial
To evaluate the efficacy and safety of yttrium-90 carbon microspheres in patients with unresectable colorectal liver metastases
The efficacy and safety of yttrium-90 carbon microspheres in patients with unresectable colorectal liver metastases remain unknown. This multicentre, prospective, open-label, single-arm trial is designed to evaluate the safety and efficacy of yttrium-90 carbon microspheres in patients with unresectable colorectal liver metastases. The primary endpoints are the progression-free survival rates of liver target lesions. While the secondary endpoints include the safety, tumor control, and the distribution characteristics of yttrium-90 carbon microspheres. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01042691 -
Isolated Liver Perfusion With Oxaliplatin
|
Phase 1 | |
| Not yet recruiting |
NCT04062721 -
Local Immunomodulation After Radiofrequency of Unresectable Colorectal Liver Metastases
|
Phase 1 |